November is Prostate Cancer Awareness Month, and it highlights the importance of early detection and treatment of this prevalent men’s health issue.
Prostate cancer is the second most common cancer among men globally. In the United States alone, it affects 1 in 8 men. The power of awareness lies in these numbers – with early detection, the five-year survival rate is nearly 100%!
While early-stage prostate cancer may be asymptomatic, advanced stages can manifest through changes in the urinary habits, blood in urine, or pelvic discomfort. Awareness of these signs and seeking timely medical attention could be crucial in the treatment of prostate cancer, as early intervention is key. Advancements in imaging technologies and biomarker research are offering more accurate and less invasive diagnostic tools.
Treatment options range from active surveillance of slow-growing tumors to surgery, radiation therapy, and hormone therapy for more aggressive cases. Personalized treatment plans, informed by thorough diagnostics, are crucial for improving outcomes.
GCT is taking an active part in cancer treatment and is an expert in conducting Oncology clinical trials. Please contact us at bd@gctrials.com to learn more about our experience.